Medigene AG
XETRA MDG1.DE
Medigene AG EBIT Margin for the year ending December 31, 2023
-
Medigene AG EBIT Margin for the year ending December 31, 2022 was -27.97%, a 70.55% change year over year.
-
Medigene AG EBIT Margin for the year ending December 31, 2021 was -94.99%, a 70.32% change year over year.
-
Medigene AG EBIT Margin for the year ending December 31, 2020 was -320.08%, a -74.81% change year over year.
-
Medigene AG EBIT Margin for the year ending December 31, 2019 was -183.11%, a 34.09% change year over year.
| Date | EBIT Margin | EPS (Basic) | EPS (Diluted) | Shares (Basic, Weighted) |
|---|
Don’t Miss A Beat
| CEO | Dr. Selwyn Ho MB BS, MBBS |
| IPO Date | June 30, 2000 |
| Location | Germany |
| Headquarters | Lochhamer Strasse 11 |
| Employees | 87 |
| Sector | Healthcare |
| Industries | |
Medigene AG, a biotechnology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company is developing personalized T cell-based therapies with a focus on T cell receptor-modified T cells in the areas of unmet medical needs, which are in clinical development. It also focuses on dendritic cell vaccines and T cell-specific monoclonal antibodies. In addition, the company focuses on developing and marketing RhuDex for hepatology and gastroenterology indications. Medigene AG has a strategic partnership with 2seventy bio, Inc. for the development of T cell receptors. The company also has research collaboration agreements on novel cancer antigens for immunotherapies with the Université de Montréal; and with Cytovant Sciences Co. Ltd. It has operations in Europe, the United States, Asia, and internationally. The company was founded in 1994 and is headquartered in Munich, Germany.
Past 5 years
USD 8.55
StockViz Staff
February 5, 2025
Any question? Send us an email